Abstract
Helicobacter pylori is the primary cause of peptic ulcer disease and an etiologic agent in the development of gastric cancer. H. pylori infection is curable with regimens of multiple antimicrobial agents, and antimicrobial resistance is a leading cause of treatment failure. The Helicobacter pylori Antimicrobial Resistance Monitoring Program (HARP) is a prospective, multicenter U.S. network that tracks national incidence rates of H. pylori antimicrobial resistance. Of 347 clinical H. pylori isolates collected from December 1998 through 2002, 101 (29.1%) were resistant to one antimicrobial agent, and 17 (5%) were resistant to two or more antimicrobial agents. Eighty-seven (25.1%) isolates were resistant to metronidazole, 45 (12.9%) to clarithromycin, and 3 (0.9%) to amoxicillin. On multivariate analysis, black race was the only significant risk factor (p <0.01, hazard ratio 2.04) for infection with a resistant H. pylori strain. Formulating pretreatment screening strategies or providing alternative therapeutic regimens for high-risk populations may be important for future clinical practice.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1088-1094 |
| Number of pages | 7 |
| Journal | Emerging Infectious Diseases |
| Volume | 10 |
| Issue number | 6 |
| State | Published - Jun 2004 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Microbiology (medical)
Cite this
Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States. / Duck, William M.; Sobel, Jeremy; Pruckler, Janet M.; Song, Qunsheng; Swerdlow, David; Friedman, Cindy; Sulka, Alana; Swaminathan, Balasubra; Taylor, Tom; Hoekstra, Mike; Griffin, Patricia; Smoot, Duane; Peek, Rick; Metz, David C.; Bloom, Peter B.; Goldschmid, Steven; Parsonnet, Julie; Triadafilopoulos, George; Perez-Perez, Guillermo I.; Vakil, Nimish; Ernst, Peter; Czinn, Steve; Dunne, Donald; Gold, Ben D.
In: Emerging Infectious Diseases, Vol. 10, No. 6, 06.2004, p. 1088-1094.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antimicrobial resistance incidence risk and factors among Helicobacter pylori-infected persons, United States
AU - Duck, William M.
AU - Sobel, Jeremy
AU - Pruckler, Janet M.
AU - Song, Qunsheng
AU - Swerdlow, David
AU - Friedman, Cindy
AU - Sulka, Alana
AU - Swaminathan, Balasubra
AU - Taylor, Tom
AU - Hoekstra, Mike
AU - Griffin, Patricia
AU - Smoot, Duane
AU - Peek, Rick
AU - Metz, David C.
AU - Bloom, Peter B.
AU - Goldschmid, Steven
AU - Parsonnet, Julie
AU - Triadafilopoulos, George
AU - Perez-Perez, Guillermo I.
AU - Vakil, Nimish
AU - Ernst, Peter
AU - Czinn, Steve
AU - Dunne, Donald
AU - Gold, Ben D.
PY - 2004/6
Y1 - 2004/6
N2 - Helicobacter pylori is the primary cause of peptic ulcer disease and an etiologic agent in the development of gastric cancer. H. pylori infection is curable with regimens of multiple antimicrobial agents, and antimicrobial resistance is a leading cause of treatment failure. The Helicobacter pylori Antimicrobial Resistance Monitoring Program (HARP) is a prospective, multicenter U.S. network that tracks national incidence rates of H. pylori antimicrobial resistance. Of 347 clinical H. pylori isolates collected from December 1998 through 2002, 101 (29.1%) were resistant to one antimicrobial agent, and 17 (5%) were resistant to two or more antimicrobial agents. Eighty-seven (25.1%) isolates were resistant to metronidazole, 45 (12.9%) to clarithromycin, and 3 (0.9%) to amoxicillin. On multivariate analysis, black race was the only significant risk factor (p <0.01, hazard ratio 2.04) for infection with a resistant H. pylori strain. Formulating pretreatment screening strategies or providing alternative therapeutic regimens for high-risk populations may be important for future clinical practice.
AB - Helicobacter pylori is the primary cause of peptic ulcer disease and an etiologic agent in the development of gastric cancer. H. pylori infection is curable with regimens of multiple antimicrobial agents, and antimicrobial resistance is a leading cause of treatment failure. The Helicobacter pylori Antimicrobial Resistance Monitoring Program (HARP) is a prospective, multicenter U.S. network that tracks national incidence rates of H. pylori antimicrobial resistance. Of 347 clinical H. pylori isolates collected from December 1998 through 2002, 101 (29.1%) were resistant to one antimicrobial agent, and 17 (5%) were resistant to two or more antimicrobial agents. Eighty-seven (25.1%) isolates were resistant to metronidazole, 45 (12.9%) to clarithromycin, and 3 (0.9%) to amoxicillin. On multivariate analysis, black race was the only significant risk factor (p <0.01, hazard ratio 2.04) for infection with a resistant H. pylori strain. Formulating pretreatment screening strategies or providing alternative therapeutic regimens for high-risk populations may be important for future clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=2542580999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2542580999&partnerID=8YFLogxK
M3 - Article
VL - 10
SP - 1088
EP - 1094
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
SN - 1080-6040
IS - 6
ER -